Season 2 (2021-2030)

Metabolic - Small Molecules (20)

Modality Indication Targets Stage Company Project No. Detail
1 Lead compound generation of DYRK1B inhibitor for NASH treatment
Small Molecules Liver fibrosis DYRK1B Lead Therasid Bioscience Inc. RS-2023-00283399
2 Discovery of lead compounds based on increase of lipolysis and energy expenditure to treat obesity
Small Molecules Obesity ALK7 Lead Gachon University RS-2023-00282576
3 Development of BKCa Channel Agonism Based New Drug Lead Compounds for Overactive Bladder Symptom
Small Molecules Bladder disease BKCa Lead GIST RS-2023-00258812
4 Development of KARS1-target drug candidate with broad and high efficacy for treatment of NASH (non-alcoholic steatohepatitis)
Small Molecules NASH KARS1 Candidate Zymedi RS-2023-00218823
5 Development of STK25 inhibitor for treatment of nonalcoholic steatohepatitis
Small Molecules NASH STK25 Lead Korea Research Institute of Chemical Technology RS-2023-00218351
6 A First-in-Class Treatment for Non-alcoholic Steatohepatitis
Small Molecules NASH HTR2A Phase 1 JD BIOSCIENCE INC. RS-2023-00218035
7 Drug development for Duchenne muscular dystrophy by increasing mRNA stability
Small Molecules Duchenne muscular dystrophy NMD Lead RiboTech HN22C0723
8 Discovery of dual A2A adeosine receptor agonist/A3 adenosine antagonist as anti-obesity drug
Small Molecules Obesity A2AAR, A3AR Lead Seoul National University HN22C0687
9 LPA1 antagonist AMS-III-1086; Pre-clinical study for liver fibrosis treatment
Small Molecules Liver fibrosis LPAR1 Preclinical am SCIENCES HN22C0594
10 Treatment of NASH using autophagy enhancer ameliorateing organelle stress
Small Molecules NASH TFEB Hit LysoTech HN22C0278
11 Development of peripheral cannabinoid 1 receptor antagonists targeting diabetes and metabolic disease using AI/CADD-based technology
Small Molecules Diabetes CB1R Lead Sungkyunkwan University HN22C0203
12 Developing treatment for metabolic disease targeting PPARγ phosphorylation based on adipocyte remodeling
Small Molecules Diabetes, Obesity PPARγ S273 Hit Korea Research Institute of Bioscience and Biotechnology HN22C0120
13 Discovery of hit and lead compounds based on oral IP6 kinase inhibition to treat obesity
Small Molecules Obesity IP6K Hit Korea Advanced Institute of Science and Technology HN21C1265
14 JP-2266: Novel SGLT1/2 dual inhibitor for the treatment of diabetes mellitus
Small Molecules Diabetes SGLT1/2 Phase 1 Jeil Pharmaceutical Co., Ltd. HN21C0675
15 Development of a PPAR/AMPK dual agonist for treatment of diabetes and metabolic syndrome
Small Molecules Diabetes PPARγ, AMPA Lead Seoul National University Hospital HN21C0497
16 Development of PAK4 inhibitor as anti-diabetes drug
Small Molecules Diabetes PAK4 Hit Jeonbuk National University HN21C0447
17 Development of Lead compounds as a Deubiquitinase USP1 Inhibitor for Non-Alcoholic Fat Liver Diseases Therapy
Small Molecules NASH USP1 Lead Yonsei University HN21C0153
18 Development of lead compounds as a sphingomyelin synthase 1 inhibitor to reduce the hepatocyte lipotoxicity for the treatment of liver cirrhosis
Small Molecules Cirrhosis SMS1 Hit Seoul National University HN21C1150
19 Development of HIT compounds of MLKL inhibitors for treatment of nonalcoholic fatty liver disease
Small Molecules NASH MLKL Hit Hanyang University HN21C1149
20 Development of lead for intestinal glucotonic therapeutics based on atypical PKC activation for treatment of metabolic syndrome
Small Molecules Diabetes, Obesity Atypical PKC Hit Yonsei University HN21C1008
BACK